Gene · 8658
Papers2,155
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,155
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Toward a Sustainable Energy Production System Based on Concentrated Solar Power Plants: Social and Water Availability Issues. | ACS Sustain Chem Eng | 2026 | 41756683 | PubTator, text mining | PubMed |
| Tankyrases and Their Binding Proteins: Origins of Their Roles in Diverse Cellular Pathways. | Cells | 2026 | 41744791 | PubTator, text mining | PubMed |
| Exploring the microbial metabolomes for Wnt pathway modulators: a multi-scale computational pipeline targeting Tankyrase in colorectal cancer. | In Silico Pharmacol | 2026 | 41727353 | PubTator, text mining | PubMed |
| β-Catenin-Facilitated Glycolytic Reprogramming Fuels TNBC Progression: Therapeutic Blockade with XAV939. | Technol Cancer Res Treat | 2026 | 41700965 | PubTator, text mining | PubMed |
| Reduced CHMP7 Expression Compromises Telomere Integrity in Mammalian Cells. | Cells | 2026 | 41677621 | PubTator, text mining | PubMed |
| SH3BP5L triggers the RAB11A-regulated integrin recycling network implicated in breast cancer metastasis. | J Clin Invest | 2026 | 41623179 | PubTator, text mining | PubMed |
| Discovery of tankyrase scaffolding inhibitor specifically targeting the ARC4 peptide binding domain. | Structure | 2026 | 41619733 | PubTator, text mining | PubMed |
| Basroparib inhibits YAP-driven cancers by stabilizing angiomotin. | Mol Oncol | 2026 | 41569232 | PubTator, text mining | PubMed |
| Synthesis of triazolopyrimidinone- and imidazotriazinone-based tankyrase inhibitors: Identification of Basroparib (STP1002) as a clinical candidate. | Bioorg Med Chem Lett | 2026 | 41565125 | PubTator, text mining | PubMed |
| Tankyrase-1-mediated PARsylation directs TFEB partner switching to regulate selective Wnt target gene expression. | Mol Cells | 2026 | 41519382 | PubTator, text mining | PubMed |
| Discovery of Fused Isoquinolinone/Triazole as a Scaffold for Tankyrase and PARP Inhibition. | J Med Chem | 2026 | 41455111 | PubTator, text mining | PubMed |
| Ubiquitin pathway blockade reveals endogenous ADP-ribosylation marking PARP7 and AHR for degradation. | EMBO J | 2026 | 41326691 | PubTator, text mining | PubMed |
| GC/MS analysis and computational evaluation of C. cinerea EO constituents for colorectal cancer: Molecular docking, dynamics, and quantum chemical insights into Cis-Verbenyl acetate. | Comput Biol Chem | 2026 | 41172603 | PubTator, text mining | PubMed |
| Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase. | Cancer Discov | 2026 | 41036949 | PubTator, text mining | PubMed |
| Bioengineering gradients for controlled embryo and organ modeling. | Curr Opin Biomed Eng | 2025 | 42211317 | PubTator, text mining | PubMed |
| Targeted therapy for liver cancer: Current status and future directions. | Bioimpacts | 2025 | 41716515 | PubTator, text mining | PubMed |
| Characterization of Differential GPX4 Essentiality Between Intrahepatic and Extrahepatic Cholangiocarcinoma via Leveraging of a Large-Scale Functional Genomic Screen. | Int J Mol Sci | 2025 | 41465418 | PubTator, text mining | PubMed |
| A Facile and Reproducible Method for the Purification of Peptide- and Protein-Functionalized DNA Nanostructures. | JACS Au | 2025 | 41450627 | PubTator, text mining | PubMed |
| Dual Repurposing Strategy: Rivaroxaban and Ciprofloxacin as a Synergistic Anticancer Therapy in Cervical Cancer: Insight into Inhibition of Metastasis via Targeting the EMT Pathway. | Asian Pac J Cancer Prev | 2025 | 41312948 | PubTator, text mining | PubMed |
| Microcirculation-Promoting Effect of Escin on Cutaneous Tissue via Gsk3β Down-Regulation. | Curr Issues Mol Biol | 2025 | 41150788 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8658/papers?page=2